

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Claude Philippe Bertrand, et al :

APPLICATION NO.: To Be Assigned

Examiner: To Be Assigned

FILING DATE: Herewith

Group Art Unit: To Be Assigned

TITLE: Therapeutic Use of Alpha-2-Delta Ligands :

Mail Stop Patent Applications
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Commissioner:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.


It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date:

Dec 12 / 03

Respectfully submitted,


William F. Mulholland, II
Attorney for Applicant(s)
Reg. No. 45,684

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-5590

EXPRESS MAIL NO. 9271824709US

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				ATTY. DOCKET NO. PC26146A				SERIAL NO. To Be Assigned			
				APPLICANT Claude Philippe Bertrand, et al							
				FILING DATE Herewith				GROUP To Be Assigned			

Page 1 of 1										U.S. PATENT DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US	6	1	0	6	8	6	4	22 Aug 00	Dolan et al	424	488	
	US	4	0	2	4	1	7	5	17 May 77	Satzinger et al	260	468 J	
	US	5	5	6	3	1	7	5	8 Oct 96	Silverman et al	514	561	

FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	WO	9	3	2	3	3	8	3	25 Nov 93	International	C07C	263/04		
	EP	1	1	9	2	9	4	4	3 April 02	EPO	A61K	31/197		
	WO	0	0	6	6	0	9	6	9 Nov 00	International	A61K	31/00		
	WO	0	0	6	7	7	4	2	16 Nov 00	International	A61K	31/00		
	WO	9	1	1	1	1	7	2	8 Aug 91	International	A61K	9/00		
	WO	9	4	0	2	5	1	8	3 Feb 94	International	C08B	37/16		
	WO	9	8	5	5	1	4	8	10 Dec 98	International	A61K	47/48		
	WO	9	7	3	3	8	5	8	18 Sept 97	International	C07C	229/28		
	WO	9	7	3	3	8	5	9	18 Sept 97	International	C07C	229/28		
	WO	9	9	3	1	0	5	7	24 June 99	International	C07D	211/26		
	WO	9	9	2	1	0	7	4	29 April 99	International	G06F	1/32		
	WO	9	7	2	9	1	0	1	14 Aug 97	International	C07D	309/04		
	WO	2	0	8	5	8	3	9	31 Oct 02	International	C07C	229/28		
	WO	9	9	3	1	0	7	5	24 June 99	International	C07D	257/04		
	WO	9	9	2	1	8	2	4	6 May 99	International	C07C	229/28		
	WO	0	1	9	0	0	5	2	29 Nov 01	International	C07C	271/22		
	WO	0	1	2	8	9	7	8	26 April 01	International	C07C	229/28		
	EP	0	6	4	1	3	3	0	17 Oct 01	EPO	C07C	29/00		
	WO	9	8	1	7	6	2	7	30 April 98	International	C07C	229/22		
	WO	0	0	7	6	9	5	8	21 Dec 00	International	C07C	229/08		
	WO	0	3	0	8	2	8	07	9 Oct 03	International	C07C	229/08		
	EP	1	1	7	8	0	3	4	6 Feb 02	EPO	C07C	233/83		
	EP	1	2	0	1	2	4	0	2 May 02	EPO	A61K	31/40		
	WO	9	9	3	1	0	7	4	24 June 99	International	C07D	257/00		
	WO	0	3	0	0	0	6	42	3 Jan 2003	International	C07C	203/04		
	WO	0	2	2	2	5	6	8	21 March 02	International	C07C	323/58		X
	WO	0	0	2	3	0	8	7	27 April 00	International	A61K	35/26		
	WO	0	2	3	0	8	8	1	18 April 02	International	C07C	311/64		
	WO	0	2	1	0	0	3	92	19 Dec 02	International	A61K	31/195		
	WO	0	2	1	0	0	3	47	19 Dec 02	International	A61K	-----		
	WO	0	2	4	2	4	1	4	30 May 02	International	C12N	-----		
	WO	0	2	3	2	7	3	6	25 April 02	International	B60T	8/88		
	WO	0	2	2	8	8	8	1	11 April 02	International	C07J	5/00		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Gee, et al., J. Biol. Chem. 271, 10, pgs 5768-5776, 1996,
	Gong et al., J. Membr. Biol. 184, 1, pgs 35-43, 2001
	E. Marais, et al., Mol. Pharmacol. 59, 5, pgs 1243-1248, 2001
	N. Qin, et al., Mol. Pharmacol., 62, 3, pgs 485-496, 2002
	Fehrenbacher et al., Pain, Vol. 105, issues 1-2, Sept 2003, pgs 133-141
	Tachykinin et al., J. Auton. Pharmacol., 1993, 13, pgs 23-93
	Halebian, Aug 1975, J. Pharm Sci, 64, 8, pgs 1269-1288
	Wermuth C.G., Chemistry and Industry, 1980, pgs 433-435
	Palomino, Drugs of the Future, 1990, 15(4), pgs 361-368
	Lalloo, et al., J. Appl Physiol, 1995, 79, pgs 1082-1087

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXPRESS MAIL NO. EU271824709US